OtherJun 12, 2026, 05:11 PM
bioAffinity Technologies Files S-1 for Stock Offering
AI Summary
bioAffinity Technologies, Inc. has filed an S-1 registration statement for an offering of 2,631,579 shares of common stock at an assumed price of $1.52 per share, with an estimated $3.4 million in proceeds intended for working capital. The company, which develops noninvasive diagnostic tests for lung cancer, also noted recent positive case studies and significant year-over-year growth in unit sales for its CyPath® Lung test in Q1 2026. It is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Highlights
- bioAffinity Technologies, Inc. filed an S-1 registration statement on June 12, 2026.
- The company is offering 2,631,579 shares of common stock at an assumed price of $1.52 per share.
- The offering also includes pre-funded warrants and placement agent warrants.
- The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
- Proceeds are estimated at $3.4 million, intended for working capital and general corporate purposes.
- The company develops noninvasive diagnostic tests for early-stage lung cancer using flow cytometry and AI.
- Recent developments include a patient case study showing CyPath® Lung's utility and 146% unit sales growth for Q1 2026 YoY.
Price Impact
More from BIAF